Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
June 25 2021 - 4:30PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
biopharmaceutical company focused on the development of therapeutic
drugs for the treatment of liver disease arising from non-alcoholic
steatohepatitis ("NASH"), today announced that its 2021 Annual
Meeting of Stockholders, scheduled for June 25, 2021, has been
adjourned due to a lack of quorum. The adjourned meeting will be
held at 9:00 a.m. Eastern Time on Friday, July 23, 2021. The record
date for determining stockholders eligible to vote on the proposals
at the Annual Meeting remains April 29, 2021. A stockholder may use
one of the following simple methods to vote:
- Vote by Internet
at www.proxyvote.com until 11:59 PM EDT on July 22, 2021
using the control number appearing on the proxy card.
- Vote by mail by
marking, dating and signing the proxy card, and returning it in the
postage-paid envelope provided to Philadelphia Stock Transfer,
Inc.
- Vote at the Annual
Meeting.
The Company strongly encourages any eligible
stockholder that has not yet voted their shares, or provided voting
instructions to their broker or other record holder, to do so
promptly. No action is required by any stockholder who has
previously delivered a proxy and who does not wish to revoke or
change that proxy.
If you have any questions or need
assistance voting your shares, please call Kingsdale Advisors
at:
North American Toll Free Phone:
1-800-749-9052
Email: contactus@kingsdaleadvisors.com
Call Collect Outside North America:
416-867-2272
About Hepion Pharmaceuticals
Hepion’s lead drug candidate, CRV431, is a
potent inhibitor of cyclophilins, which are involved in many
disease processes. CRV431 is currently in clinical-phase
development for the treatment of NASH, with the potential to play
an important role in the overall treatment of liver disease - from
triggering events through to end-stage disease. CRV431 has been
shown to reduce liver fibrosis and hepatocellular carcinoma tumor
burden in experimental models of NASH; and has demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms, in nonclinical studies.
Hepion has created a proprietary AI platform,
called AI-POWR™, which stands for Artificial
Intelligence - Precision Medicine;
Omics (including genomics, proteomics,
metabolomics, transcriptomics, and lipidomics);
World database access; and
Response and clinical outcomes. Hepion intends to
use AI-POWR™ to help identify which NASH patients will best respond
to CRV431, potentially shortening development timelines and
increasing the delta between placebo and treatment groups. In
addition to using AI-POWR™ to drive its ongoing Phase 2a NASH
program, Hepion will use the platform to identify additional
potential indications for CRV431 to expand the company's footprint
in the cyclophilin inhibition therapeutic space.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimated,” and “intend,” among others.
These forward-looking statements are based on Hepion
Pharmaceuticals’ current expectations and actual results could
differ materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; risks associated with delays,
increased costs and funding shortages caused by the COVID-19
pandemic; uncertainties with respect to lengthy and expensive
clinical trials, that results of earlier studies and trials may not
be predictive of future trial results; uncertainties of government
or third party payer reimbursement; limited sales and marketing
efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. As with any drug candidates under
development, there are significant risks in the development,
regulatory approval, and commercialization of new products. There
are no guarantees that future clinical trials discussed in this
press release will be completed or successful, or that any product
will receive regulatory approval for any indication or prove to be
commercially successful. Hepion Pharmaceuticals does not undertake
an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Hepion
Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and
other periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect:
(646) 274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Sep 2023 to Sep 2024